RECORDATI POLSKA Sp. z.o.o - Poland
History of Recordati Group

About usHistory of Recordati Group

1926 Recordati was founded in Correggio (Emilia, Italy) as “Laboratorio Farmacologico Reggiano” by Giovanni Recordati.
1927 Launch of Antispasmina colica®, gastrointestinal tract antispasmodic.
1930 Launch of Solvobil®, cholagogue and laxative.
1935 Launch of Tefamin®, cardiotonic, diuretic and antihypertensive, followed by its associations.
1938 Launch of Simpamina®, stimulant of the vegetative nervous system.
1953 Recordati moves the company to the current site in Milan, the most important Italian economic centre.
1956 Launch of Recordil® (efloxate), coronary vasodilator.
1961 An exclusive license agreement is signed, later renewed until 2005, with Syntex Corporation (now part of Roche), at that time at the leading edge of research into the study and synthesis of steroidal hormones.  
1962 Remeflin® (dimefline), respiratory analeptic, registered and commercialized.
1973 Flavoxate (Genurin®/Urispas® and other brands), a urinary anti-spasmodic still widely used, was launched. It was the frst drug synthesized and developed in Italy to receive FDA approval in the USA.  
1977 Antoral® (tibezonium iodide), an oral antiseptic, launched in Italy, performs well in a number of countries.  
1984 The company is listed on the Italian stock exchange (Borsa Italiana, now part of the London Stock Exchange Group).  
1986 Launch of Lomexin® (fenticonazole), a dermatological and gynecological anti-mycotic, still widely used in clinical practice in many countries.  
1995 Recordati outlines its growth and development strategy embarking on a process of internationalization. A subsidiary was established in Spain, now called Casen Recordati.  
1997 First launch of Zanidip® (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati.  
1999 Recordati acquires the French pharmaceutical company Doms Adrian to establish a Group direct presence in the second largest pharmaceutical market in Europe.  
2000 Expansion in France continues with the acquisition of the Bouchara pharmaceutical group.  
2001 The two French companies are merged and the resulting subsidiary becomes Bouchara Recordati. Conversion of all savings shares into ordinary shares and subsequent 2:1 stock split.  
2002 The U.K. Medicines Control Agency granted a Product License (marketing approval) for Zanidip® (lercanidipine) 20 mg tablets.  
2003 The 20mg strength of lercanidipine launched in a number of countries including Germany, France and Australia.  
2004 The pharmaceutical pipeline is strengthened through the launch of new drugs.  
2005 Recordati gains access to the largest pharmaceutical market in Europe and the third largest worldwide with the acquisition of Merckle Recordati in Germany, now Recordati Pharma. Establishment of Recordati Pharmaceuticals in the United Kingdom and of Recordati Hellas Pharmaceuticals in Greece. Recordati opens a new active pharmaceutical ingredients plant in Ireland. 4:1 stock split.  
2006 Recordati acquires the Grupo Jaba companies in Portugal, today Jaba Recordati. Zanipress®, a fxed combination of lercanidipine and enalapril was approved for sale by BfArM (the German medicines agency).  
2007 The frst launch of Zanipress®. Acquisition of Orphan Europe, a European pharmaceutical group dedicated to the development, registration, marketing and distribution of unique drugs for the treatment of rare and orphan diseases.  
2008 Acquisition of the French companies FIC and FIC Médical which are dedicated to the registration and the promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries. Acquisition of Yeni Ilaç (today Recordati Ilaç), a well-known pharmaceutical company in Turkey.  
2009 Acquisition of Herbacos-Bofarma, a pharmaceutical company operating in the Czech and Slovak markets.  
2010 European Marketing Authorization obtained for silodosin (Urorec®, Silodyx®), an alpha blocker indicated for treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Carbaglu® (carglumic acid) approved by the Food and Drug Administration (FDA) in the U.S. for the treatment of NAGS defciency. Acquisition of ArtMed International, a company dedicated to the promotion of pharmaceutical products in Romania. Positive outcome of the Decentralized Procedure for the approval of pitavastatin (Livazo®, Alipza®) in Europe.  
2011 European approval to extend the use of Carbaglu® (carglumic acid) to treat hyperammonaemia due to either of the three main organic acidaemias. Acquisition of Dr. F. Frik Ilaç A.S. in Turkey. Acquisition of Procto-Glyvenol® a product indicated for the treatment of haemorrhoids. Recordati Polska is established in Poland. Launch of Livazo® (pitavastatin) in Spain and in Portugal.  
2012 Acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany, the rights to fve well-known product lines in Russia and other C.I.S. countries, and the leading oral care line of products bearing the Dentosan® trademark in Italy. Recordati reinforces its presence in Poland with the acquisition of Farma-Projekt. An agreement was signed with Erytech Pharma for the commercialization and distribution of Graspa® for the treatment of Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe. Recordati acquires all rights to a portfolio of products indicated for the treatment of rare and other diseases in the United States of America which is now marketed there by Recordati Rare Diseases.  
2013 Acquisition of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana (Tunis) and a modern cGMP certifed production facility, which represents a strategic platform to establish a direct presence in North Africa. Acquisition of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid, production facilities in Utebo, Zaragoza.  
2014 U.S. Food and Drug Administration (FDA) granted orphan drug designation for the use of Carbaglu® (carglumic acid) in the treatment of organic acidemias (OAs). License agreement signed with Apricus Biosciences Inc. for the marketing and sales of Vitaros® (alprostadil), a topical product for the treatment of erectile dysfunction, and with Plethora Solutions for the commercialization of Fortacin™, a topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation.  
2015 Establishment of subsidiaries in Brazil, Mexico and Colombia for the commercialization of treatments for rare diseases. Carbaglu® (carglumic acid) was authorized for sale by Health Canada for the treatment of acute and chronic hyperammonaemia due to NAGS defciency.  
2016 Acquisition of Italchimici S.p.A., an Italian pharmaceutical company, and Pro Farma AG, a Swiss pharmaceutical company that operates also in Austria. Agreement with AP-HP (Assistance Publique – Hopitaux de Paris) for the development and commercialization of a product for the treatment of acute decompensation episodes in patients affected by Maple Syrup Urine Disease (MSUD), a severe metabolic disorder. A license agreement with Gedeon Richter was signed to commercialize cariprazine, a novel atypical antipsychotic.  
2017 Approval of Cystadrops® the frst eye-drop solution containing cysteamine hydrochloride approved in the European Union for the treatment of corneal cystine crystal deposits. Agreement with the Meyer Hospital in Florence (Italy) for the development of a treatment for pre-term babies affected by retinopathy of prematurity. Acquisition from AstraZeneca the European rights to Seloken®/Seloken® ZOK (metoprolol succinate) and Logimax® (metoprolol succinate and felodipine). Agreement with MimeTech for the development and commercialization of a peptidomimetic of human nerve growth factor for the treatment of neurotrophic keratitis. Acquisition of three Bayer Consumer Health brands in France, Transipeg®, TransipegLib® and Colopeg®.  
2018 Acquisition from Mylan of the rights to Cystagon® (cysteamine bitartrate), indicated for the treatment of proven nephropathic cystinosis in children and adults, for certain territories, including Europe. Acquisition of Natural Point S.r.l., an Italian company active in the food supplements market whose main product is Magnesio Supremo®. A license agreement was signed with Helsinn for the exclusive rights to Ledaga® (chlormethine hydrochloride), a novel gel formulation indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma worldwide, worldwide excluding the United States, China, Hong Kong and Israel. The product has been granted Orphan Drug Designation in Europe and is approved by the European Commission. Acquisition of Tonipharm S.A.S., a French company active mainly in the self-medication market. The company’s main products are Ginkor®, OTC treatments based on ginko biloba which are very well known on the French market, and Alodont®, a line of products used for oral hygiene. Launch of Reagila® (cariprazine), a new atypical antipsychotic for the treatment of schizophrenia, in Europe.  
2019 License agreement with Aegerion Pharmaceuticals Inc., for the exclusive rights to commercialize Juxtapid®, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan.  
Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, has successfully executed its strategy aimed at establishing a direct presence in the key markets across all continents. Several companies formerly operating under the name of Orphan Europe were renamed Recordati Rare Diseases, which is today the global brand of Recordati’s organization dedicated to treatments for rare diseases.
Acquisition from Novartis of worldwide rights to Signifor® and Signifor® LAR® for the treatment of Cushing’s disease and acromegaly. The agreement also covers the acquisition of worldwide rights to Isturisa® (osilodrostat), an innovative drug for the treatment of endogenous Cushing’s syndrome.  
2020 The European Commission and the Food and Drug Administration (FDA) approved the marketing of the orphan pharmaceutical product Isturisa® (osilodrostat). Application for marketing in Japan (JNDA, Japanese New Drug Application) also submitted to the Ministry of Health, Labor and Welfare. Transfer from Novartis to Recordati Rare Diseases Inc. of the marketing authorizations for Signifor® and Signifor® LAR in the US and start of direct marketing of these products in this market. Started also for Isturisa® the commercialization with the first sales in the United States, France and Germany. Approval granted by the FDA for the marketing in the US of Cystadrops® 0.37% (cysteamine-based ophthalmic solution), a new viscous eye drop solution for the treatment of patients living with cystinosis. Signed an exclusive licensing agreement with ARS Pharmaceuticals for the commercialization in 93 countries including those of the European Union, of ARS-1, an epinephrine-based nasal spray, in the process of being registered with the European Medicines Agency (EMA), for the emergency treatment of severe allergic reactions which could lead to anaphylaxis. Approved by the Board of Directors and by the Extraordinary Shareholders' Meeting the reverse merger by incorporation of Rossini Investimenti S.p.A. and FIMEI S.p.A. in Recordati S.p.A.